288 related articles for article (PubMed ID: 31141829)
21. Shedding New Light: Novel Therapies for Common Disorders in Children with Neurofibromatosis Type I.
Pillay-Smiley N; Fletcher JS; de Blank P; Ratner N
Pediatr Clin North Am; 2023 Oct; 70(5):937-950. PubMed ID: 37704352
[TBL] [Abstract][Full Text] [Related]
22. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT.
Gross AM; Achée C; Hart SE; Brewer L; Baldwin A; Wolters PL; Widemann BC;
Future Oncol; 2024 May; 20(14):877-890. PubMed ID: 38869947
[TBL] [Abstract][Full Text] [Related]
23. Giant gluteal and vesical plexiform neurofibromas in a patient with neurofibromatosis type 1: a case report.
Sassi I; Bouida MA; Hasnaoui A; Zemni I; Ben Dhieb T
J Med Case Rep; 2024 Jan; 18(1):15. PubMed ID: 38216958
[TBL] [Abstract][Full Text] [Related]
24. Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis.
Brown R
Curr Oncol Rep; 2023 Dec; 25(12):1409-1417. PubMed ID: 37906356
[TBL] [Abstract][Full Text] [Related]
25. Plexiform neurofibromas in NF1: toward biologic-based therapy.
Packer RJ; Gutmann DH; Rubenstein A; Viskochil D; Zimmerman RA; Vezina G; Small J; Korf B
Neurology; 2002 May; 58(10):1461-70. PubMed ID: 12041525
[TBL] [Abstract][Full Text] [Related]
26. Impact of trametinib on the neuropsychological profile of NF1 patients.
Lalancette E; Cantin É; Routhier MÈ; Mailloux C; Bertrand MC; Kiaei DS; Larouche V; Tabori U; Hawkins C; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; McKeown T; Ospina LH; Vairy S; Ramaswamy V; Coltin H; Sultan S; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Caru M; Dehaes M; Jabado N; Perreault S; Lippé S
J Neurooncol; 2024 May; 167(3):447-454. PubMed ID: 38443693
[TBL] [Abstract][Full Text] [Related]
27. Management of neurofibromatosis type 1-associated plexiform neurofibromas.
Fisher MJ; Blakeley JO; Weiss BD; Dombi E; Ahlawat S; Akshintala S; Belzberg AJ; Bornhorst M; Bredella MA; Cai W; Ferner RE; Gross AM; Harris GJ; Listernick R; Ly I; Martin S; Mautner VF; Salamon JM; Salerno KE; Spinner RJ; Staedtke V; Ullrich NJ; Upadhyaya M; Wolters PL; Yohay K; Widemann BC
Neuro Oncol; 2022 Nov; 24(11):1827-1844. PubMed ID: 35657359
[TBL] [Abstract][Full Text] [Related]
28. Association between benign and malignant peripheral nerve sheath tumors in NF1.
Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
[TBL] [Abstract][Full Text] [Related]
29. Clinical impact of selumetinib on pediatric elephantiasis neuromatosa.
Blegen K; Ortiz-Romero SE; Juarez O; Voeller J
Pediatr Dermatol; 2022 Sep; 39(5):764-766. PubMed ID: 35739628
[TBL] [Abstract][Full Text] [Related]
30. French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study.
Wolkenstein P; Chaix Y; Entz Werle N; Amini-Adle M; Barbarot S; Boileau C; Miled A; Rashid T; Aerts I
Eur J Med Genet; 2023 May; 66(5):104734. PubMed ID: 36868501
[TBL] [Abstract][Full Text] [Related]
31. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Anderson MK; Johnson M; Thornburg L; Halford Z
Ann Pharmacother; 2022 Jun; 56(6):716-726. PubMed ID: 34541874
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Mek Inhibitors in the Treatment of Plexiform Neurofibromas: A Retrospective Study.
Cacchione A; Fabozzi F; Carai A; Colafati GS; Baldo GD; Rossi S; Diana M; Megaro G; Milano GM; Macchiaiolo M; Crocoli A; De Ioris MA; Boccuto L; Secco DE; Zama M; Agolini E; Tomà P; Mastronuzzi A
Cancer Control; 2023; 30():10732748221144930. PubMed ID: 36598023
[TBL] [Abstract][Full Text] [Related]
33. Selumetinib: the first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma.
Mukhopadhyay S; Maitra A; Choudhury S
Curr Med Res Opin; 2021 May; 37(5):789-794. PubMed ID: 33683166
[TBL] [Abstract][Full Text] [Related]
34. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
[TBL] [Abstract][Full Text] [Related]
35. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1.
Waggoner DJ; Towbin J; Gottesman G; Gutmann DH
Am J Med Genet; 2000 May; 92(2):132-5. PubMed ID: 10797438
[TBL] [Abstract][Full Text] [Related]
36. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
de Blank PMK; Gross AM; Akshintala S; Blakeley JO; Bollag G; Cannon A; Dombi E; Fangusaro J; Gelb BD; Hargrave D; Kim A; Klesse LJ; Loh M; Martin S; Moertel C; Packer R; Payne JM; Rauen KA; Rios JJ; Robison N; Schorry EK; Shannon K; Stevenson DA; Stieglitz E; Ullrich NJ; Walsh KS; Weiss BD; Wolters PL; Yohay K; Yohe ME; Widemann BC; Fisher MJ
Neuro Oncol; 2022 Nov; 24(11):1845-1856. PubMed ID: 35788692
[TBL] [Abstract][Full Text] [Related]
37. Plexiform neurofibroma of uterus: a rare manifestation of neurofibromatosis 1.
Shahzad R; Younas F
J Coll Physicians Surg Pak; 2014 Mar; 24 Suppl 1():S22-3. PubMed ID: 24717994
[TBL] [Abstract][Full Text] [Related]
38. Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening.
Kraniak JM; Chalasani A; Wallace MR; Mattingly RR
Exp Neurol; 2018 Jan; 299(Pt B):289-298. PubMed ID: 29055717
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
Widemann BC; Babovic-Vuksanovic D; Dombi E; Wolters PL; Goldman S; Martin S; Goodwin A; Goodspeed W; Kieran MW; Cohen B; Blaney SM; King A; Solomon J; Patronas N; Balis FM; Fox E; Steinberg SM; Packer RJ
Pediatr Blood Cancer; 2014 Sep; 61(9):1598-602. PubMed ID: 24753394
[TBL] [Abstract][Full Text] [Related]
40. Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.
Staser K; Yang FC; Clapp DW
Annu Rev Pathol; 2012; 7():469-95. PubMed ID: 22077553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]